Navigation Links
Eidogen-Sertanty Licenses TIP to the FDA
Date:12/8/2009

SAN DIEGO, Dec. 8 /PRNewswire/ -- Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

Under the terms of the license, scientists within NCTR will have access to the complete TIP structural knowledgebase via onlineTIP as well as access to the TIP/Workgroup technology for internal research. Eidogen-Sertanty will also participate in several NCTR-led projects including the multi-year PADRE project (MAQC-IV), which is focusing on the modeling of drug-protein interactions to identify new genetic variations that may lead to serious adverse drug reactions.

"We're extremely pleased to have licensed the TIP technology to the FDA/NCTR," said Dr. Steven Muskal, Eidogen-Sertanty's Chief Executive Officer. "We very much look forward to having a positive impact in the FDA's effort to predict serious adverse drug reactions at the individual patient level."


Eidogen-Sertanty contact:

Steve Muskal
760-651-2885
pr@eidogen-sertanty.com

About Eidogen-Sertanty

Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty's unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services, please visit www.eidogen-sertanty.com.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Eidogen-Sertanty


'/>"/>
SOURCE Eidogen-Sertanty
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
2. GeneGo Licenses MetaCore to Proteostasis Therapeutics
3. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
4. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
5. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
6. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
7. Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane
8. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
9. Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
10. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
11. Implicit Licenses Clinical Stage Antibody Program From Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):